Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease
Open Access
- 1 January 2008
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 14 (3), 331-337
- https://doi.org/10.3748/wjg.14.331
Abstract
Primary sclerosing cholangitis (PSC) is a chronic progressive disorder of unknown aetiology characterised by chronic inflammation and stricture formation of the biliary tree. Symptoms include itch and lethargy and in advanced cases cholangitis and end-stage liver disease, however increasing numbers of asymptomatic individuals are being identified. The disease is rare in the general population but is strongly associated with inflammatory bowel disease (IBD) affecting up to 5% of patients with Ulcerative Colitis, with a slightly lower prevalence (up to 3.6%) in Crohn's disease. The strength of this association means that the vast majority (> 90%) of patients with PSC also have IBD, although many may have only mild gastro-intestinal symptoms. Usually IBD presents before PSC, although vice-versa can occur and the onset of both conditions can be separated in some cases by many years. Mean age of diagnosis of PSC is in the fifth decade of life with a strong male predominance. Risk is increased in those with a family history of PSC, suggesting a genetic predisposition and the disease is almost exclusive to non-smokers. The ulcerative colitis associated with PSC is characteristically mild, runs a quiescent course, is associated with rectal sparing, more severe right sided disease, backwash ileitis and has a high risk of pouchitis post-colectomy. Most worrisome is the high risk of colorectal malignancy which necessitates routine colonoscopic surveillance. Cholangiocarcinoma is also a frequent complication of PSC with a 10%-15% lifetime risk of developing this condition. Treatment with high dose ursodeoxycholic acid offers some chemoprotective effects against colorectal malignancy and may decrease symptoms, biochemical and histological progression of liver disease. Small duct PSC patients characteristically have normal cholangiography, and liver biopsy is required for diagnosis, it appears to have a more favourable prognosis. Autoimmune Hepatitis (AIH) is also more prevalent in patients with IBD, with up to 16% of patients with AIH also having ulcerative colitis. A small subgroup of patients have a AIH-PSC overlap syndrome and the management of these patients depends on liver histology, serum IgM levels, autoantibodies, degree of biochemical cholestasis and cholangiography as some of these patients may respond to immunosupression.Keywords
This publication has 93 references indexed in Scilit:
- The Value of Serum CA 19-9 in Predicting Cholangiocarcinomas in Patients with Primary Sclerosing CholangitisDigestive Diseases and Sciences, 2005
- Increased prevalence of primary sclerosing cholangitis among first-degree relativesJournal of Hepatology, 2005
- Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring systemJournal of Hepatology, 2000
- International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitisJournal of Hepatology, 1999
- Ursodeoxycholic acid therapy for primary sclerosing cholangitis: Results of a 2-year randomized controlled trial to evaluate single versus multiple daily dosesJournal of Hepatology, 1998
- Ursodiol for Primary Sclerosing CholangitisThe New England Journal of Medicine, 1997
- Epidemiology of primary sclerosing cholangitis in SpainJournal of Hepatology, 1994
- Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitisJournal of Hepatology, 1992
- Liver damage in juvenile inflammatory bowel diseaseLiver International, 1990
- Ursodeoxycholic acid for primary sclerosing cholangitisJournal of Hepatology, 1990